Recently, oncogenic KRAS was found to promote an immunosuppressive tumor microenvironment through the CXCL3‐CXCR2 pathway in MDSCs, providing a potential combination therapeutic strategy for the treatment of advanced colorectal cancer (Liao et al., 2019). Here, CXCL3 is linked to colorectal cancer.